{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-009767","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.552627+00:00","generated_at":"2026-06-06T11:02:41.429832+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Clearside reduces sublicense fees to high single digit; maintenance fees set $250K-$500K for 2023-2028","bullets":["Sublicense percentage reduced from low double digits to high single digits for fees received from sublicensees.","Maintenance fees: $250K for 2023-2025, $350K for 2026, $400K for 2027, $500K for 2028.","2023 maintenance fee of $250K due within 5 days of amendment execution (Jan 31, 2024).","Reduced sublicense fee excludes R&D reimbursements, IP value transfers, and stock payments.","Royalty rate on product sales remains unchanged at low single digit."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-009767","json":"https://secwatch.observer/filing/0000950170-24-009767.json","markdown":"https://secwatch.observer/filing/0000950170-24-009767.md","text":"https://secwatch.observer/filing/0000950170-24-009767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024009767/0000950170-24-009767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024009767/clsd-20240131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T11:02:41.429832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"287e539d7ad7d7236d7888521bfd6d303ef82a44","claim":"Clearside Biomedical, Inc. amended License Agreement with Emory University valued at reduction of Sublicense Percentage from a low double digit to a high single digit; revised annual li (effective 2024-01-31).","evidence_excerpt":"On January 31, 2024 (the “ Amendment Execution Date ”), Clearside Biomedical, Inc. (the “ Company ”), Emory University (“ Emory ”) and Georgia Tech Research Corporation (together with Emory, the “ Licensor ”), entered into an amendment (the “ Amendment ”) to the Company’s License Agreement with Licensor dated July 4, 2012 (as amended, the “ License Agreement ”), pursuant to which the Company received a worldwide exclusive license to specified patents relating to methods and devices for drug delivery using a microinjector.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024009767/0000950170-24-009767-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Emory University"},{"label":"Value","value":"reduction of Sublicense Percentage from a low double digit to a high single digit; revised annual li"},{"label":"Effective","value":"2024-01-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}